Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review

Introduction: The past decade has seen increasingly rapid advances in understanding the pathogenic nature of adult-onset Still’s disease (AOSD) and its shared symptoms with the systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) blocking agents are key elements in the treatment. In t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Claudia Kedor, Stylianos Tomaras, Daniel Baeumer, Eugen Feist
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/dee9f4fe5cf94ac3bd725ba8d1336885
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dee9f4fe5cf94ac3bd725ba8d1336885
record_format	dspace
spelling	oai:doaj.org-article:dee9f4fe5cf94ac3bd725ba8d13368852021-12-01T00:06:50ZUpdate on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review1759-721810.1177/1759720X211059598https://doaj.org/article/dee9f4fe5cf94ac3bd725ba8d13368852021-11-01T00:00:00Zhttps://doi.org/10.1177/1759720X211059598https://doaj.org/toc/1759-7218Introduction: The past decade has seen increasingly rapid advances in understanding the pathogenic nature of adult-onset Still’s disease (AOSD) and its shared symptoms with the systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) blocking agents are key elements in the treatment. In this updated systematic review, we focus on studies on efficacy and safety of IL-1 blockers published in the past 5 years and review on latest available therapies. Methods: We conducted searches using Medline, Biosis, Embase, and Cochrane databases between 2016 and 2021 using the terms AOSD, IL1, IL-18, canakinumab, anakinra, tadekinig, and rilonacept and if applicable their trade names. Duplicates, case reports, and manuscripts with incomplete data were excluded. Results: Of the 1013 screened publications, 17 were eligible after careful selection. We only found two published randomized controlled studies in the past 5 years. Review manuscripts of rare diseases, like our work, usually rely on retrospective studies and case series. Anakinra and canakinumab can be successfully used as first- or further-line treatment in patients with AOSD refractory to steroids. A homogeneous outcome is not established yet. Thus, a combination of clinical and laboratory tests can support the experienced clinician in the decision-making process. Conclusion: The approval of IL-1 inhibitors for AOSD brought us into a new era in the treatment of AOSD. The overall efficacy-safety profile of the IL-1 inhibitors is favorable reflecting a targeted approach as standard of care. We can expect that the successful treatment of AOSD with IL-1 inhibition will facilitate further clinical and basic research with impact on other auto-inflammatory and hyper-inflammatory conditions.Claudia KedorStylianos TomarasDaniel BaeumerEugen FeistSAGE PublishingarticleDiseases of the musculoskeletal systemRC925-935ENTherapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Claudia Kedor Stylianos Tomaras Daniel Baeumer Eugen Feist Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review
description	Introduction: The past decade has seen increasingly rapid advances in understanding the pathogenic nature of adult-onset Still’s disease (AOSD) and its shared symptoms with the systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) blocking agents are key elements in the treatment. In this updated systematic review, we focus on studies on efficacy and safety of IL-1 blockers published in the past 5 years and review on latest available therapies. Methods: We conducted searches using Medline, Biosis, Embase, and Cochrane databases between 2016 and 2021 using the terms AOSD, IL1, IL-18, canakinumab, anakinra, tadekinig, and rilonacept and if applicable their trade names. Duplicates, case reports, and manuscripts with incomplete data were excluded. Results: Of the 1013 screened publications, 17 were eligible after careful selection. We only found two published randomized controlled studies in the past 5 years. Review manuscripts of rare diseases, like our work, usually rely on retrospective studies and case series. Anakinra and canakinumab can be successfully used as first- or further-line treatment in patients with AOSD refractory to steroids. A homogeneous outcome is not established yet. Thus, a combination of clinical and laboratory tests can support the experienced clinician in the decision-making process. Conclusion: The approval of IL-1 inhibitors for AOSD brought us into a new era in the treatment of AOSD. The overall efficacy-safety profile of the IL-1 inhibitors is favorable reflecting a targeted approach as standard of care. We can expect that the successful treatment of AOSD with IL-1 inhibition will facilitate further clinical and basic research with impact on other auto-inflammatory and hyper-inflammatory conditions.
format	article
author	Claudia Kedor Stylianos Tomaras Daniel Baeumer Eugen Feist
author_facet	Claudia Kedor Stylianos Tomaras Daniel Baeumer Eugen Feist
author_sort	Claudia Kedor
title	Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review
title_short	Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review
title_full	Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review
title_fullStr	Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review
title_full_unstemmed	Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review
title_sort	update on the therapy of adult-onset still’s disease with a focus on il-1-inhibition: a systematic review
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/dee9f4fe5cf94ac3bd725ba8d1336885
work_keys_str_mv	AT claudiakedor updateonthetherapyofadultonsetstillsdiseasewithafocusonil1inhibitionasystematicreview AT stylianostomaras updateonthetherapyofadultonsetstillsdiseasewithafocusonil1inhibitionasystematicreview AT danielbaeumer updateonthetherapyofadultonsetstillsdiseasewithafocusonil1inhibitionasystematicreview AT eugenfeist updateonthetherapyofadultonsetstillsdiseasewithafocusonil1inhibitionasystematicreview
_version_	1718406170632257536

Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review

Ejemplares similares